Keyphrases
Long-term Survival
100%
Triple-negative Breast Cancer
100%
Response to Neoadjuvant Therapy
100%
Non-triple-negative Breast Cancer
58%
Pathological Complete Response
41%
Complete Response Rate
41%
Neoadjuvant Chemotherapy
16%
Residual Disease
16%
Breast Cancer
8%
Overall Survival
8%
Relapse Rate
8%
Death Rate
8%
Recurrence Rate
8%
Progression-free Survival
8%
Progesterone Receptor
8%
Clinical Parameters
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
8%
Estrogen Receptor
8%
Epidermal Growth Factor Receptor
8%
Organ-specific
8%
Low Risk
8%
Clinical Database
8%
Overall Survival Rate
8%
MD Anderson Cancer Center
8%
Method Analysis
8%
Patient Analysis
8%
Pathologic Parameters
8%
Response to Neoadjuvant Chemotherapy
8%
Bone Recurrence
8%
Visceral Metastases
8%
Post-recurrence Survival
8%
Biochemistry, Genetics and Molecular Biology
Survival Rate
100%
Long Term Survival
100%
Overall Survival
66%
Mortality Rate
33%
Progression Free Survival
33%
Progesterone Receptor
33%
Epidermal Growth Factor Receptor
33%
Estrogen Receptor
33%
Medicine and Dentistry
Triple Negative Breast Cancer
100%
Long Term Survival
100%
Neoadjuvant Therapy
100%
Survival Rate
15%
Neoadjuvant Chemotherapy
15%
Overall Survival
10%
Minimal Residual Disease
10%
Recurrence Risk
10%
Receptor
5%
Breast Cancer
5%
Recurrent Disease
5%
Mortality Rate
5%
Progression Free Survival
5%
Malignant Neoplasm
5%
Gamma Urogastrone
5%
Epidermal Growth Factor Receptor 2
5%
Visceral Metastasis
5%
Progesterone Receptor
5%
Estrogen Receptor
5%
Nursing and Health Professions
Long Term Survival
100%
Triple Negative Breast Cancer
100%
Neoadjuvant Therapy
100%
Survival Rate
15%
Neoadjuvant Chemotherapy
15%
Overall Survival
10%
Recurrence Risk
10%
Minimal Residual Disease
10%
Cancer Center
5%
Breast Cancer
5%
Progression Free Survival
5%
Recurrent Disease
5%
Mortality Rate
5%
Receptor
5%
Visceral Metastasis
5%
Gamma Urogastrone
5%
Progesterone Receptor
5%
Epidermal Growth Factor Receptor 2
5%
Estrogen Receptor
5%
Immunology and Microbiology
Long Term Survival
100%
Survival Rate
100%
Overall Survival
66%
Mortality Rate
33%
Progression Free Survival
33%
Gamma Urogastrone
33%
Pharmacology, Toxicology and Pharmaceutical Science
Triple Negative Breast Cancer
100%
Long Term Survival
100%
Chemotherapy
15%
Survival Rate
15%
Overall Survival
10%
Recurrence Risk
10%
Minimal Residual Disease
10%
Malignant Neoplasm
5%
Receptor
5%
Breast Cancer
5%
Recurrent Disease
5%
Progression Free Survival
5%
Mortality Rate
5%
Estrogen Receptor
5%
Epidermal Growth Factor Receptor 2
5%
Gamma Urogastrone
5%
Visceral Metastasis
5%
Progesterone Receptor
5%